Early Access — free while we kick the tires
EdgarHawk

Leach Jacob Steven

President & COO

Officer
2 filings analyzed · 1 company · Latest 2025-11-10

Companies

Company Buys Sells Direction
DEXCOM INC DXCM 2 1 Net buying

Activity

November 2025
2025-11-10 DEXCOM INC DXCM
high
Buy
18,200 shares
$1,001,702
Significance 6/10

DXCM President & COO Leach buys 18.2K shares for $1.0M on 2025-11-10; stock down 39.6% from 52-week high

Leach Jacob Steven, President & COO of Dexcom, executed two separate purchases on 2025-11-10 totaling 18,200 shares for $1,001,701.90 at a blended average price of $55.04, increasing his holdings by 5.8%. The transaction occurred as the stock trades at $54.84, down 39.6% from its 52-week high of $90.75 and down 15.8% over the prior 30 days. Leach's prior trading record at DXCM shows mixed outcomes: his three prior sales (2025-03-12, 2024-03-12, 2023-04-20) produced a 90-day well-timed rate of 33.33%, with only 1 of 3 sales being well-timed at the 90-day horizon. The company reports strong fundamentals with revenue of $1,209,300,000.00, net income of $283,800,000.00, and 11.3% annual revenue growth, though trading at a P/E of 29.64. The magnitude of this buy—$1.0M—and its execution during a period of substantial stock decline merit monitoring for signals about management's assessment of valuation at these depressed price levels.

March 2025
2025-03-14 DEXCOM INC DXCM
medium
Sell
14,076 shares
$990,670
Significance 4/10

DXCM COO Leach sells 14,076 shares ($990.7K) at $70.38; stock down -49.7% from 52-week high

Jacob Steven Leach, EVP and Chief Operating Officer, sold 14,076 shares of Dexcom at $70.38 on 2025-03-12, reducing his holdings from 327,573 shares to 313,497 shares—a 4.3% reduction. The transaction occurred as the stock trades -49.7% below its 52-week high of $140.45, with sharp declines over the past 30 days (-15.7%) and 90 days (-8.4%). Leach's cross-ticker track record shows 2 prior sells with a 50.00% well-timed rate and average 90-day return of -3.2%, while at Dexcom specifically his prior 2 sales (2024-03-12 and 2023-04-20) produced mixed 90-day results (−13.3% and +6.9% respectively). The timing of this sale relative to the stock's recent sharp depreciation and broader market position merits observation alongside the company's fundamentals: latest quarterly revenue of $994,200,000.00, net income of $134,600,000.00, 11.3% annual revenue growth, and a current P/E of 38.63.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access